- New York Biotechnology Association (“NYBA”) 21st Annual Meeting, Corporate Showcase: May 2, 2012 at 2:00 PM (EDT) in New York City
- Wall Street 1-2-1 Conference: May 9, 2012 in Orlando, Florida (meetings throughout day)
- Security Research Association (“SRA”) Spring Growth Conference: May 15, 2012 at 2:00 PM (PDT, tentative scheduled time) in San Francisco
TONIX’s management team will provide an overview of the company and discuss the clinical development of its lead product candidates in development for the treatment of fibromyalgia and post-traumatic stress disorder and TONIX’s business strategy. Management’s presentations at the NYBA Corporate Showcase and SRA Conference will be webcast live and can be accessed through the company’s website using the following link:
Members of the investment community who are interested in meeting with management during these conferences are encouraged to call Sharon Weinstein at 212-564-4700 to schedule a meeting.
TONIX Pharmaceuticals is developing new therapies for challenging disorders of the central nervous system. The Company targets conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. TONIX reformulates approved pharmaceutical active ingredients to design products with optimal safety, efficacy and predictability. Its most advanced product candidates, TNX-102 for FM and TNX-105 for PTSD, are novel dosage formulation of cyclobenzaprine, the active ingredient in two U.S. FDA-approved muscle relaxants. To learn more about the Company and its pipeline of treatments for CNS conditions, please visit www.tonixpharma.com